<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2401210464
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Vantra
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AVANAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        331.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vantra contains the active substance avanafil. It belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. Vantra is a treatment for adult men suffering from erectile dysfunction (also known as impotence). This is when you cannot get, or keep a hard, erect penis suitable for sexual activity. Vantra works by helping the blood vessels in your penis to relax. This increases the blood flow into your penis, helping it stay hard and erect when you get sexually excited. Vantra does not cure your condition. It is important to note that Vantra only works if you are sexually stimulated. You and your partner will still need to use foreplay to get ready for sex &ndash; just as you would if you were not taking a medicine to help you. Vantra will not help you if you do not have erectile dysfunction. Vantra is not for women.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Vantra:</strong></p><p>&bull; If you are allergic to avanafil or any of the other ingredients of this medicine (listed in section 6). &bull; If you are taking &ldquo;nitrate&rdquo; medicines for chest pain (angina), such as amyl nitrite or glyceryl trinitrate. Vantra can increase the effects of these medicines and severely lower your blood pressure. &bull; If you are taking medicines for HIV or AIDS such as ritonavir, indinavir, saquinavir, nelfinavir or atazanavir. &bull; If you are taking medicines for fungal infections such as ketoconazole, itraconazole or&nbsp;voriconazole or certain antibiotics for bacterial infections, such as clarithromycin or telithromycin. &bull; If you have a serious cardiac problem. &bull; If you have had a stroke or heart attack in the last 6 months. &bull; If you have low blood pressure or high blood pressure not controlled by medicines. &bull; If you have chest pain (angina) or you get chest pain during sexual intercourse. &bull; If you have a serious liver or kidney problem. &bull; If you have loss of vision in one eye due to not enough blood getting to your eye (nonarteritic ischemic optic neuropathy [NAION]). &bull; If certain serious eye problems run in your family (such as retinitis pigmentosa). &bull; If you are taking riociguat. This drug is used to treat pulmonary arterial hypertension (i.e., high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e., high blood pressure in the lungs secondary to blood clots). PDE5 inhibitors have been shown to increase the hypotensive effects of this medicine. If you are taking riociguat or are unsure tell your doctor. Do not take Vantra if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Vantra.</p><p><strong>Take special care with Vantra</strong></p><p>Talk to your doctor or pharmacist before taking Vantra: &bull; If you have heart trouble. It may be risky for you to have sexual intercourse. &bull; If you suffer from priapism that is a persistent erection lasting 4 hours or more. This can happen in men with conditions like sickle cell disease, multiple myeloma or leukaemia. &bull; If you have a physical condition that affects the shape of your penis (such as angulation, Peyronie&rsquo;s disease or cavernosal fibrosis). &bull; If you have any bleeding disorder or active peptic ulceration. If any of the above apply to you talk to your doctor or pharmacist before taking Vantra. Check with your doctor or pharmacist if you are not sure. Problems with your sight or hearing Some men taking medicines like Vantra have had problems with their sight and hearing &ndash; see &ldquo;Serious side effects&rdquo; in section 4 for more details. It is not known if these problems are related directly to Vantra, other diseases that you may have or a combination of factors.</p><p><strong>Children and adolescents</strong></p><p>Vantra should not be taken by children and adolescents under 18 years of age</p><p><strong>Taking other medicines and Vantra</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because Vantra can affect the way some other medicines work. Also some other medicines can affect the way Vantra works. In particular, tell your doctor and do not take Vantra if you are taking &ldquo;nitrate&rdquo; medicines for chest pain (angina) such as amyl nitrite or glyceryl trinitrate. Vantra has been shown to increase the effects of these medicines and severely lower your blood pressure. Also do not take Vantra if you are taking medicines for HIV or AIDS such as ritonavir, indinavir, saquinavir, nelfinavir or atazanavir or if you are taking medicines for fungal infections such as ketoconazole, itraconazole or voriconazole or certain antibiotics for bacterial infections, such as clarithromycin or telithromycin (see beginning of section 2 under &ldquo;Do not take Vantra&rdquo;).</p><p>Tell your doctor or pharmacist if you are taking any of the following medicines: &bull; so called &ldquo;alpha-blockers&rdquo; &ndash; for prostate problems or for lowering your high blood pressure. &bull; medicines for an irregular heartbeat (&ldquo;arrhythmia&rdquo;) such as quinidine, procainamide, amiodarone or sotalol. &bull; antibiotics for infections such as erythromycin. &bull; phenobarbital or primidone &ndash; for epilepsy. &bull; carbamazepine &ndash; for epilepsy, to stabilise your mood or for certain types of pain. &bull; other medicines that may reduce the breakdown of Vantra in the body (&ldquo;moderate CYP3A4 inhibitors&rdquo;) including amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir, and verapamil. &bull; riociguat. Do not use Vantra together with other treatments for erectile dysfunction such as sildenafil, tadalafil or vardenafil. If any of the above apply to you talk to your doctor or pharmacist before taking Vantra. Check with your doctor or pharmacist if you are not sure</p><p>&nbsp;</p><p><strong>Fertility </strong></p><p>There was no effect on sperm movement or structure after single 200 mg oral doses of avanafil in healthy volunteers. Currently, no data on sperm development in healthy adult males and adult males with mild erectile dysfunction are available.</p><p><strong>Taking Vantra with food and drink</strong></p><p>Grapefruit juice can increase exposure to the medicine and should be avoided within 24 hours prior to taking Vantra. Drinking alcohol at the same time as taking Vantra may increase your heart rate and lower your blood pressure. You may feel dizzy (especially when standing), have a headache or feel your heart beating in your chest (palpitations). Drinking alcohol may also decrease your ability to get an erection.</p><p><strong>Driving and using machines</strong></p><p>Vantra can make you feel dizzy or affect your vision. If this happens, do not drive, cycle, use tools or machines</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is a 100 mg tablet, as needed. You should not take Vantra more than once a day. Tell your doctor if you think Vantra is too strong or too weak. He/she may suggest you switch to a different dose of this medicine. Dose adjustments can also be required if Vantra is used together with certain other medicines. If you are taking a medicine such as erythromycin, amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir or verapamil (&bdquo;moderate CYP3A4 inhibitors‟) the recommended dose of Vantra is a 100 mg tablet, with an interval of at least 2 days between doses. You should take Vantra about 30 minutes (50 mg) or approximately 15 to 30 minutes (100 mg and 200 mg) before you have sexual intercourse. Remember that Vantra will only help you to get an erection if you are sexually stimulated. Vantra can be taken with or without food; if taken with food, it may take longer to work.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Serious side effects</strong></p><p><strong>Stop taking Vantra and see a doctor straight away if you notice any of the following serious side effects &ndash; you may need urgent medical treatment:</strong></p><p>&bull; An erection that will not go away (&ldquo;priapism&rdquo;). If you get an erection that lasts more than 4 hours, this must be treated as soon as possible or lasting damage can happen to your penis (including not being able to get erections) &bull; Blurred vision &bull; Sudden decrease or loss of vision in one or both eyes &bull; Sudden decrease or loss of hearing (sometimes you may also feel dizzy or have ringing in your ears) Stop taking Vantra and see a doctor straight away, if you notice any of the serious side effects above</p><p>&nbsp;</p><p><strong>Other side effects include:</strong></p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>&bull; headache &bull; flushing &bull; nasal congestion</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>&bull; feeling dizzy &bull; feeling sleepy or very tired &bull; sinus congestion &bull; back pain &bull; hot flush &bull; feeling out of breath when you exert yourself &bull; heartbeat changes seen on a heart tracing (ECG) &bull; increased heart beat &bull; feeling your heartbeat in your chest (palpitations) &bull; indigestion, feeling or being sick to your stomach &bull; blurry vision &bull; raised liver enzymes</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>&bull; influenza &bull; influenza-like illness &bull; stuffy or runny nose &bull; hay fever &bull; congestion in the nose, sinuses or upper part of the airway bringing air into the lungs &bull; gout &bull; trouble sleeping (insomnia)&nbsp;&bull; premature ejaculation &bull; feeling strange &bull; feeling unable to keep still &bull; chest pain &bull; serious chest pain &bull; fast heart beat &bull; high blood pressure &bull; dry mouth &bull; stomach ache or heartburn &bull; pain or discomfort in the lower abdomen &bull; diarrhea &bull; rash &bull; pain in the lower back or side of lower chest &bull; muscle aches or pains &bull; muscle spasms &bull; frequent urination &bull; penile disorder &bull; spontaneous erection without sexual stimulation &bull; itching in the genital area &bull; feeling weak or tired all the time &bull; swelling in the feet or ankles &bull; increased blood pressure &bull; pink or red urine, blood in the urine &bull; abnormal extra sound from the heart &bull; an abnormal blood test result for a prostate test called &ldquo;PSA&rdquo; &bull; an abnormal blood test result for bilirubin, a chemical produced from the normal breakdown of red blood cells &bull; an abnormal blood test result for creatinine, a chemical excreted in the urine, and a measure of kidney function &bull; weight gain &bull; fever</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister and carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month. Store below 30&deg;C. This medicine does not require any special storage condition. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is avanafil. Each tablet of Vantra 50 mg tablets contains 50 mg of avanafil. Each tablet of Vantra 100 mg tablets contains 100 mg of avanafil. Each tablet of Vantra 200 mg tablets contains 200 mg of avanafil. &bull; The other ingredients are Mannitol B.P, Fumaric Acid NF, Klucel EXF Pharm (Hydroxypropyl Cellulose ), Iron Oxide Yellow, Hydroxypropyl Methylcellulose Low-S., Calcium Carbonate Precipitated, and Magnesium Stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vantra 50 mg tablet is a yellow color, oblong, biconvex, uncoated tablet, plain on both sides.
Vantra 100 mg tablet is a yellow color, oblong, biconvex, bevelled edge uncoated tablet plain
on both sides.
Vantra 200 mg tablet is a yellow color, oblong, biconvex, bevelled edge uncoated tablet plain
on both sides.
Each pack of Vantra 50 mg tablets contains 4, 12, and 30 tablets.
Each pack of Vantra 100 mg tablets contains 4, and 12 tablets.
Each pack of Vantra 200 mg tablets contains 4, and 12 tablets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO Al-Qassim pharmaceutical plant Saudi Pharmaceutical Industries &amp; Medical Appliance Corporation Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 05/2016. 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي ڤانترا على المادة الفعالة أڤانافيل. وهو ينتمي إلى مجموعة من الأدوية تسمى مثبطات فوسفودايستريز من النوع 5 (5 PDE .(ڤانتراهو علاج للرجال البالغين الذين يعانون من ضعف الإنتصاب (المعروف أيضا باسم العجز الجنسي). هي الحالة عندما لا يمكنك الحصول، أو الحفاظ على قضيب منتصب بصورة مناسبة للنشاط الجنسي. يعمل ڤانترا على استرخاء الأوعية الدموية في القضيب. وهذا يزيد من تدفق الدم إلى القضيب، مما يساعد على البقاء في وضع الإنتصاب عند الاثارة الجنسية. لا يعالج ڤانترا حالتك. من المهم أن نلاحظ أن ڤانترا يعمل فقط إذا كنت مثار جنسيا. لا تزال أنت و شريكة حياتك بحاجة إلى استخدام المداعبة للاستعداد لممارسة الجنس - تماما كما تفعل لو كنت لا تأخذ دواء لمساعدتك. لن يساعدك ڤانترا اذا لم يكن لديك مشاكل في الإنتصاب .لا يمكن للنساء استخدام ڤانترا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول ڤانترا: &bull; إذا كنت تعاني من فرط التحسس (التأق) لمادة أڤانافيل او أي من المكونات الأخرى لهذا الدواء (المذكورة فى قسم 6.( &bull; إذا كنت تأخذ دواء &quot;نترات&quot; لعلاج آلام الصدر (الذبحة الصدرية)، مثل أميل النتريت أو ثلاثي نترات الغليسيريل .يمكن أن يزيد ڤانترا من تأثير هذه الأدوية ويسبب انخفاض شديد في ضغط الدم. &bull; إذا كنت تأخذ أدوية لفيروس نقص المناعة البشرية أو الإيدز مثل ريتونافير، اندينافير، ساكوينافير، نلفينافير أو اتازنفير. &bull; إذا كنت تأخذ أدوية العدوى الفطرية مثل كيتوكونازول، ايتراكونازول أو ڤوريكونازول أو بعض المضادات الحيوية للعدوى البكتيرية، مثل كلاريثروميسين أوتيليريثروميسين. &bull; إذا كنت تعاني من مشكلة خطيرة في القلب. &bull; إذا كنت تعاني من سكتة دماغية أو أزمة قلبية في آخر 6 أشهر.</p><p>&bull; إذا كنت تعاني من انخفاض في ضغط الدم أو ارتفاع في ضغط الدم لا تسيطر عليه الأدوية. &bull; إذا كنت تعاني من ألم في الصدر (الذبحة الصدرية) أو تشعر بآلام في الصدر أثناء الجماع. &bull; إذا كنت تعاني من مشكلة خطيرة في الكبد أو الكلى. &bull; إذا كنت تعاني من فقدان البصر في عين واحدة بسبب عدم حصول العين على ما يكفي من الدم (اعتلال العصب البصري الغير شرياني الناتج عن نقص التروية الدموية NAION . &bull; إذا كانت تعاني عائلتك من بعض المشاكل الخطيرة في العين (مثل التهاب الشبكية الصباغي). &bull; إذا كنت تأخذ ريوسيجوات. يستخدم هذا الدواء لعلاج ارتفاع ضغط الدم الشرياني الرئوي (أي ارتفاع ضغط الدم في الرئتين) وارتفاع ضغط الدم الرئوي الانسدادي التجلطي المزمن (أي ارتفاع ضغط الدم في الرئتين الناتج عن تجلط الدم). قد ً تبين أن مثبطات PDE5 تزيد من تأثيرهذا الدواء الخافض للضغط. إذا كنت تأخذ أخبر ريوسيجوات أو غير متأكد فضلا طبيبك. ً أخبرطبيبك أو الصيدلي قبل البدء بتناول لا تأخذ ڤانترا إذا كان أي من الأعراض أعلاه تنطبق عليك. إذا لم تكن متأكدا، فضلا ڤانترا.</p><p><strong>ينبغي توخي الحذر عند تناول ڤانترا</strong></p><p>تحدث إلى طبيبك أو الصيدلي قبل تناول ڤانترا: &bull; ة إذا كان لديك مشكل في القلب. قد يكون الجماع محفوفا بالمخاطر بالنسبة لك. &bull; إذا كنت تعاني من الفحولة وهو الإنتصاب المستمرالذي يدوم 4 ساعات أو أكثر. هذا يمكن أن يحدث في الرجال الذين يعانون من أمراض مثل مرض فقر الدم المنجلي، المايلوما المتعددة أو سرطان الدم. &bull; إذا كان لديك حالة بدنية تؤثرعلى شكل القضيب (مثل الإعوجاج،مرض بيروني أو تليف كاڤيرنوسال). &bull; إذا كان لديك أي اضطرابات نزفية أو قرحة هضمية نشطة. ً ڤانترا .استشر طبيبك أو قم بالتحدث مع طبيبك أو الصيدلي قبل تناول إذا كان أي من الأعراض أعلاه تنطبق عليك فضلا الصيدلي إذا لم تكن متأكدا.</p><p><u>المشاكل التى قد يتعرض لها بصرك أو سمعك</u></p><p>ً بعض الرجال الذين يتناولون أدوية مثل ڤانترا يعانون من انظر الأعراض الجانبية مشاكل مع بصرهم وسمعهم - (فضلا الخطيرة في القسم 4 لمزيد من التفاصيل). ومن غير المعروف ما إذا كانت هذه المشاكل متعلقة بصورة مباشرة بتناول ڤانترا أوالأمراض الأخرى التي قد تكون لديك أو مزيج من العوامل.</p><p>&nbsp;</p><p><strong>الأطفال والمراهقين</strong></p><p>لا ينبغي أن يؤخذ ڤانترا من قبل الأطفال والمراهقين دون سن 18 سنة من العمر</p><p><strong>تناول ڤانترا مع الأدوية الأخرى</strong></p><p>أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت ڤانترا في الآونة الأخيرة أو قد تتناول أي أدوية أخرى. وذلك لأن ڤانترا يمكن أن يؤثر على طريقة عمل بعض الأدوية الأخرى. أيضا بعض الأدوية الأخرى يمكن أن تؤثر على الطريقة التي يعمل بها ڤانترا. على وجه الخصوص، أخبر طبيبك ولا تأخذ ڤانترا إذا كنت تأخذ أدوية &quot;نترات&quot; للألم في الصدر (الذبحة الصدرية) مثل أميل النتريت أو ثلاثي نترات الغليسيريل. وقد تبين أن ڤانترا يزيد من تأثير هذه الأدوية و يسبب انخفاض شديد في ضغط الدم. أيضا لا تأخذ ڤانترا إذا كنت تأخذ أدوية لفيروس نقص المناعة البشرية أو الإيدز مثل ريتونافير، اندينافير، ساكوينافير، نلفينافير أو اتازنفير أو إذا كنت تأخذ أدوية العدوى الفطرية مثل كيتوكونازول، ايتراكونازول أوڤوريكونازول أو بعض ً 2 تحت عنوان لا تأخذ المضادات الحيوية للعدوى البكتيرية، مثل كلاريثروميسين أو تليريثرومايسين انظر بداية القسم (فضلا ڤانترا). أخبر طبيبك أو الصيدلي إذا كنت تأخذ أي من الأدوية التالية: &bull; ما يسمى &quot;حاصرات ألفا&quot; - لمشاكل البروستاتا أو لتخفيض ضغط دمك المرتفع. &bull; أدوية عدم انتظام ضربات القلب (عدم انتظام ضربات القلب) مثل كينيدين، بروكاييناميد، اميودارون أو سوتالول. &bull; المضادات الحيوية للعدوى مثل اريثروميسين. &bull; فينوباربيتال أو بريميدون - لعلاج الصرع. &bull; كاربامازيبين - لعلاج الصرع، أو لتحقيق الاستقرار في المزاج، أو لأنواع معينة من الألم.&nbsp;&bull; الأدوية الأخرى التي يمكن أن تقلل من تكسيرڤانترافي الجسم (مثبطاتCYP3A4 المتوسطة) من ضمنها امبرينافير،أبربيتانت، ديلتيازيم، فلوكونازول، فوسامبريناڤير، وفيراباميل. &bull; ريوسيجوات. لا تستخدم ڤانتراجنبا إلى جنب مع الأدوية الأخرى المستخدمة لعلاج حالات عدم القدرة على الإنتصاب مثل سيلدينافيل، تادالافيل، أو ڤاردينافيل. إذا كان أي من الأعراض أعلاه تنطبق عليك قم بالتحدث مع طبيبك أو الصيدلي قبل تناول ڤانترا .استشر طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p>&nbsp;</p><p><strong>الخصوبة </strong></p><p>ڤانترا ليس له أي تأثير على شكل أو حركة الحيوانات المنوية بعد جرعة فموية واحدة من أڤانافيل 200 ملجم على متطوعين أصحاء. لا تتوفر حاليا أية بيانات حول تطور الحيوانات المنوية في الذكور البالغين الأصحاء والذكور البالغين الذين يعانون من ضعف الإنتصاب البسيط.</p><p><strong>أخذ ڤانترا مع الطعام والشراب</strong></p><p>يمكن أن يزيد عصير الجريب فروت من التعرض للدواء ويجب تجنبه خلال 24 ساعة قبل تناول ڤانترا. شرب الكحول في نفس الوقت الذي تتناول فيه ڤانترا قد يزيد من معدل ضربات القلب و خفض ضغط الدم. قد تشعر بالدوار ً (وخصوصا عند الوقوف)،قد من قدرتك على تشعر بصداع أو بخفقان قلبك في صدرك (خفقان). شرب الكحول قد يقلل أيضا الحصول على الإنتصاب.</p><p><strong>القيادة و استخدام الآلات</strong></p><p>يمكن أن يجعلك ڤانترا تشعر بالدوار أو يؤثر على رؤيتك. إذا حدث هذا، لا تقود السيارة، ولا تستخدم الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول هذا الدواء تماما كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا. الجرعة الموصى بها هي قرص 100 مجم، عند الحاجة. يجب أن لا تأخذ ڤانترا أكثر من مرة في اليوم. أخبر طبيبك إذا كنت تعتقد أن ڤانترا قوي جدا أو ضعيف جدا.قد يقترح عليك طبيبك التحول إلى جرعة مختلفة من هذا الدواء. قد تكون بحاجة إلي تعديلات في الجرعة إذا تم استخدام ڤانترا جنبا إلي جنب مع بعض الأدوية الأخرى. إذا كنت تأخذ دواء مثل اريثروميسين، امبرينافير، أبريبيتانت، ديلتيازيم، فلوكونازول، فوسامبريناڤير أو فيراباميل (مثبطاتCYP3A4 المتوسطة) الجرعة الموصى بها من ڤانتراهو قرص 100 ملجم، مع فاصل زمني لا يقل عن يومين بين الجرعات. يجب أن تأخذ ڤانترا (50 ملجم) قبل 30 دقيقة أو ما يقارب من 15 إلي 30 دقيقة (100 ملجم و 200 ملجم) قبل الجماع الجنسي. تذكر أن ڤانترا سوف يساعد فقط في الحصول على الإنتصاب إذا كنت مثار جنسيا. يمكن تناول ڤانترا مع أو بدون الطعام. إذا أخذ مع الطعام، قد يستغرق وقتا أطول في العمل.</p><p><strong>إذا تناولت جرعة زائدة من ڤانترا</strong></p><p>إذا تناولت الكثير من ڤانترا، يجب عليك إخبار طبيبك على الفور. قد تحدث آثار جانبية أكثر من المعتاد، وقد تكون أسوأ. إذا كان لديك أي أسئلة أخرى حول استخدام ڤانترا، إسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية، يمكن لهذا الدواء أن يسبب أعراض جانبية، على الرغم من أن هذه الأعراض لا تحدث لكل من يتناول الدواء.</p><p><strong>أعراض جانبية خطيرة </strong></p><p><strong>عليك التوقف عن تناول ڤانترا ومراجعة الطبيب فورا إذا لاحظت أي من الأعراض الجانبية التالية - قد تحتاج إلى علاج طبي عاجل:</strong></p><p>&nbsp;</p><p>&bull; الإنتصاب المستمر (&quot;فحولة&quot;). إذا حدث لك الإنتصاب الذي يستمر أكثر من 4 ساعات، يجب أن يعالج في أقرب وقت ممكن أو يمكن ان يحدث ضرر دائم لقضيبك (بما في ذلك عدم القدرة على الحصول على الإنتصاب) &bull; عدم وضوح الرؤية &bull; انخفاض أو فقدان البصر المفاجئ في إحدى أو كلتا العينين &bull; انخفاض أو فقدان السمع المفاجئ (في بعض الأحيان قد تشعر أيضا بالدوار أو تشعر برنين في أذنيك) إذا لاحظت أي من الأعراض الجانبية الخطيرة أعلاه، عليك التوقف عن تناول ڤانترا ومراجعة الطبيب على الفور.</p><p><strong>وتشمل الأعراض الجانبية الأخرى:</strong></p><p><strong>أعراض جانبية شائعة (قد تؤثر في ما يصل إلى 1 من كل 10 أشخاص)</strong> &bull; الصداع &bull; احمرار &bull; احتقان الأنف</p><p><strong>أعراض جانبية غير شائعة (قد تؤثر في ما يصل إلى 1 من كل 100 شخص) &bull; </strong>الشعور بالدوار &bull; الشعور بالنعاس أو التعب الشديد &bull; احتقان الجيوب الأنفية &bull; آلام الظهر &bull; فورة ساخنة &bull; شعور بانقطاع النفس عند بذل الجهد &bull; تغيرات في ضربات القلب ينظر إليها على تتبع القلب (ECG ( &bull; زيادة ضربات القلب &bull; الشعور بدقات قلبك في صدرك (خفقان) &bull; عسر الهضم، والشعور بالغثيان في معدتك &bull; ضبابية الرؤية &bull; ار اتفع انزيمات الكبد</p><p><strong>أعراض جانبية نادرة الحدوث (قد تؤثر في ما يصل إلى 1 من كل 1000 شخص) </strong>&bull; الانفلونزا &bull; مرض يشبه الانفلونزا &bull; انسداد أو سيلان الأنف &bull; حمى القش &bull; احتقان في الأنف، الجيوب الأنفية أو الجزء العلوي من مجرى الهواء الذي يوصل الهواء إلى الرئتين &bull; النقرس &bull; صعوبة في النوم (الأرق) &bull; سرعة القذف &bull; شعور بالغرابة &bull; شعور بعدم القدرة على الحفاظ على التوازن &bull; ألم في الصدر &bull; ألم شديد في الصدر &bull; ضربات القلب السريعة &bull; ارتفاع ضغط الدم &bull; جفاف الفم &bull; ألم المعدة أو حرقة المعدة &bull; ألم أوشعور بعدم الراحة في أسفل البطن &bull; الإسهال &bull; الطفح الجلدي &bull; ألم في أسفل الظهر أوجانب من أسفل الصدر &bull; أوجاع أو آلام العضلات &bull; تشنجات عضلية &bull; كثرة التبول &bull; اضطراب القضيب &bull; الإنتصاب العفوي دون الإثارة ة الجنسي &bull; حكة في المنطقة التناسلية &bull; الشعور بالضعف أو التعب في كل وقت&nbsp;&bull; تورم في القدمين أو الكاحلين &bull; ارتفاع ضغط الدم &bull; احمرار أو تورد البول، دم في البول &bull; صوت إضافي غير طبيعي من القلب &bull; نتيجة غير طبيعية في فحص الدم لاختبار البروستاتا تسمى &quot;بي اس ايه&quot; &bull; نتيجة غير طبيعية في فحص الدم للبيليروبين، وهي مادة كيميائية تنتج من التكسرالطبيعي لخلايا الدم الحمراء &bull; نتيجة غير طبيعية في اختبارالدم للكرياتينين، وهي مادة كيميائية تفرز في البول، وتستخدم كمقياس لوظائف الكلى &bull; زيادة الوزن &bull; الحمى اذا كان لديك أي أعراض جانبية، تحدث مع طبيبك أو الصيدلي. ويشمل ذلك أي أعراض جانبية محتملة غيرمدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة (انظر التفاصيل أدناه). من خلال تبليغك عن الأعراض الجانبية يمكن أن تساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ عن متناول و نظر الأطفال. يحفظ هذا الدواء بعيدا لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المطبوع على شريط الدواء والكرتون بعد &quot;EXP &quot;تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر. يحفظ في درجة حرارة أقل من 30 درجة مئوية. لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيفية رمي الأدوية التي لم تعد تستخدم. ومن شأن هذه التدابير أن تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هي أڤانافيل. يحتوي كل قرص من ڤانترا 50 ملجم على 50 ملجم من أڤانافيل. يحتوي كل قرص من ڤانترا 100 ملجم على 100 ملجم من أڤانافيل. يحتوي كل قرص من ڤانترا 200 ملجم على 200 ملجم من أڤانافيل. &bull; المكونات الأخرى هي مانيتول بي بي و حمض فوماريك و كلوسيل إي إكي إف فارم ( هيدروكسي بروبيل السيللوز ) وأكسيد الحديد الأصفر و هيدروكسي بروبيل السيللوز منخفض إس، كربونات الكالسيوم المترسب و ستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>قرص ڤانترا 50 ملجم هو قرص أصفر اللون، مستطيل، محدب الوجهين، قرص غير مغلف، عادي على كلا الجانبين. قرص ڤانترا 100 ملجم هو قرص أصفر اللون، مستطيل، محدب الوجهين، مشطوف الحافة، قرص غير مغلف، عادي على كلا الجانبين. قرص ڤانترا 200 ملجم هو قرص أصفر اللون، مستطيل، محدب الوجهين، مشطوف الحافة، قرص غير مغلف، عادي على كلا الجانبين. تحتوي كل عبوة من أقراص ڤانترا 50 ملجم علي 4 أو 12 أو 30 قرص. تحتوي كل عبوة من أقراص ڤانترا 100 ملجم علي 4 أو 12 قرص. تحتوي كل عبوة من أقراص ڤانترا 200 ملجم علي 4 أو 12 قرص. قد لا يتم تسويق جميع العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك الحقوق التسويقية و المصنع: الدوائية مصنع الأدوية بالقصيم المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             05/2016 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vantra 50 mg tablets
Vantra 100 mg tablets
Vantra 200 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet of Vantra 50 mg tablets contains 50 mg of avanafil.
Each tablet of Vantra 100 mg tablets contains 100 mg of avanafil.
Each tablet of Vantra 200 mg tablets contains 200 mg of avanafil.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets
Vantra 50 mg tablet is a yellow color, oblong, biconvex, uncoated tablet, plain on both sides.
Vantra 100 mg tablet is a yellow color, oblong, biconvex, bevelled edge uncoated tablet plain
on both sides.
Vantra 200 mg tablet is a yellow color, oblong, biconvex, bevelled edge uncoated tablet plain
on both sides.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of erectile dysfunction in adult men. In order for Vantra to be effective, sexual stimulation is required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Use in adult men The recommended dose is 100 mg taken as needed approximately 15 to 30 minutes before sexual activity (See Section 5.1). Based on individual efficacy and tolerability, the dose may be increased to a maximum dose of 200 mg or decreased to 50 mg. The maximum recommended dosing frequency is once per day. Sexual stimulation is required for a response to treatment.</p><p>Special populations</p><p>Older men (&ge; 65 years old) Dose adjustments are not required in older patients. Limited data are available in older patients aged 70 years or above.</p><p>Renal impairment Dose adjustments are not required in patients with mild to moderate renal impairment (creatinine clearance &ge; 30 mL/min). Vantra is contraindicated in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) (see sections 4.3 and 5.2). Patients with mild or&nbsp;moderate renal impairment (creatinine clearance &ge;30 mL/min but &lt;80 mL/min) who were enrolled in phase 3 studies showed decreased efficacy compared to those with normal renal function</p><p>Hepatic impairment Vantra is contraindicated in patients with severe hepatic impairment (Child Pugh class C) (see sections 4.3 and 5.2). Patients with mild to moderate hepatic impairment (Child-Pugh class A or B) should initiate treatment with the minimum efficacious dose and adjust posology based on tolerance</p><p>Use in men with diabetes Dose adjustments are not required in diabetic patients.</p><p>Pediatric population There is no relevant use of Vantra in the pediatric population in the indication of erectile dysfunction.</p><p><u>Use in patients using other medicinal products</u></p><p>Concomitant use of CYP3A4 inhibitors Co-administration of Vantra with potent CYP3A4 inhibitors (including ketoconazole, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir and telithromycin) is contraindicated (see sections 4.3, 4.4 and 4.5). In patients receiving concomitant treatment with moderate CYP3A4 inhibitors (including erythromycin, amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir, and verapamil), the maximum recommended dose of Vantra should not exceed 100 mg, with an interval of at least 48 hours between doses (see section 4.5).</p><p><u>Method of administration </u></p><p>For oral use. If Vantra is taken with food, the onset of activity may be delayed compared to the fasted state (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Patients who are using any form of organic nitrate or nitric oxide donors (such as amyl nitrite)
(see section 4.5).
The co-administration of type 5 phosphodiesterase (PDE5) inhibitors, including Vantra, with
guanylatecyclase stimulators, such as riociguat is contraindicated as it may potentially lead to
symptomatic hypotension (see section 4.5).
Physicians should consider the potential cardiac risk of sexual activity in patients with preexisting cardiovascular disease before prescribing Vantra.
The use of Vantra is contraindicated in:
- Patients who have suffered from a myocardial infarction, stroke, or life-threatening
arrhythmia within the last 6 months;
- Patients with resting hypotension (blood pressure < 90/50 mmHg) or hypertension (blood
pressure > 170/100 mmHg);
- Patients with unstable angina, angina with sexual intercourse, or congestive heart failure
categorized as New York Heart Association Class 2 or greater.
Patients with severe hepatic impairment (Child-Pugh C).
Patients with severe renal impairment (creatinine clearance < 30 mL/min).
Patients who have loss of vision in one eye because of non-arteritic anterior ischemic optic
neuropathy (NAION), regardless of whether this episode was in connection or not with
previous PDE5 inhibitor exposure (see section 4.4).
Patients with known hereditary degenerative retinal disorders.
Patients who are using potent CYP3A4 inhibitors (including ketoconazole, ritonavir,
atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir and
telithromycin) (see sections 4.2, 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A medical history and physical examination should be undertaken to diagnose erectile dysfunction and determine potential underlying causes, before pharmacological treatment is considered.</p><p><u>Cardiovascular status</u></p><p>Prior to initiating any treatment for erectile dysfunction, physicians should consider the cardiovascular status of their patients since there is a degree of cardiac risk associated with sexual activity (see section 4.3). Vantra has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 4.5), and as such potentiates the hypotensive effect of nitrates (see section 4.3). Patients with left ventricular outflow obstruction, e.g. aortic stenosis and idiopathic hypertrophic subaortic stenosis, can be sensitive to the action of vasodilators, including PDE5 inhibitors.</p><p><u>Priapism</u></p><p>Patients who experience erections lasting 4 hours or more (priapism) should be instructed to seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result. Vantra should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie&#39;s disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).</p><p><u>Visual problems</u></p><p>Visual defects and cases of non-arteritic anterior ischaemic optic neuropathy (NAION) have been reported in connection with the intake of other PDE5 inhibitors. The patient should be advised that in case of sudden visual effects, he should stop taking Vantra and consult a physician immediately (see section 4.3)</p><p><u>Effect on bleeding</u></p><p>In vitro studies with human platelets indicate that PDE5 inhibitors do not have an effect on platelet aggregation on their own, but at supratherapeutic doses they potentiate the antiaggregatory effect of the nitric oxide donor sodium nitroprusside. In humans, PDE5 inhibitors do not appear to affect bleeding time alone or in combination with acetylsalicylic acid. There is no safety information on the administration of Vantra to patients with bleeding disorders or active peptic ulceration. Therefore, Vantra should be administered to such patients only after careful benefit-risk assessment.</p><p><u>Decreased or sudden loss of hearing</u></p><p>Patients should be advised to stop taking PDE5 inhibitors, including Vantra, and seek prompt medical attention in the event of sudden decrease or loss of hearing. These events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to the intake of PDE5 inhibitors. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors.</p><p><u>Concomitant use of alpha-blockers</u></p><p>The concomitant use of alpha-blockers and Vantra may lead to symptomatic hypotension in some patients due to additive vasodilatory effects (see section 4.5). Consideration should be given to the following: &bull; Patients should be stable on alpha-blocker therapy prior to initiating Vantra. Patients who demonstrate haemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of Vantra. &bull; In those patients who are stable on alpha-blocker therapy, Vantra should be initiated at the lowest dose of 50 mg. &bull; In those patients already taking an optimised dose of Vantra, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure when taking Vantra. &bull; The safety of combined use of Vantra and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive medicinal products.</p><p><u>Concomitant use of CYP3A4 inhibitors</u></p><p>&nbsp;</p><p>Co-administration of Vantra with potent inhibitors of CYP3A4, such as ketoconazole or ritonavir is contraindicated (see sections 4.2, 4.3 and 4.5).</p><p><u>Concomitant use of other treatments for erectile dysfunction</u></p><p>The safety and efficacy of combinations of Vantra and other PDE5 inhibitors or other treatments for erectile dysfunction have not been studied. Patients should be informed not to take Vantra in such combinations</p><p><u>Concomitant use of alcohol</u></p><p>Consumption of alcohol in combination with Vantra can increase the potential for symptomatic hypotension (see section 4.5). Patients should be advised that concurrent use of Vantra and alcohol may increase the likelihood of hypotension, dizziness, or syncope. Physicians should also advise patients on what to do in the event of postural hypotensive symptoms.</p><p><u>Populations not studied</u></p><p>Vantra has not been evaluated in patients with erectile dysfunction due to spinal cord injury or other neurological disorders and in subjects with severe renal or hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Potential for pharmacodynamic interactions with Vantra</strong></u></p><p><strong>Nitrates </strong></p><p>Vantra was shown to augment the hypotensive effects of nitrates compared to placebo in healthy subjects. This is thought to result from the combined effects of nitrates and Vantra on the nitric oxide/cGMP pathway. Therefore, administration of Vantra to patients who are using any form of organic nitrate or nitric oxide donor (such as amyl nitrite) is contraindicated. In a patient who has taken Vantra within 12 hours, where nitrate administration is deemed medically necessary in a life-threatening situation, the likelihood of a significant and potentially dangerous drop in blood pressure is increased. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate haemodynamic monitoring (see section 4.3). Medicinal products reducing systemic blood pressure As a vasodilator, Vantra may reduce systemic blood pressure. If Vantra is used in combination with another medicinal product which reduces systemic blood pressure, the additive effects may result in symptomatic hypotension (e.g. dizziness, light-headedness, syncope or nearsyncope). In phase III clinical trials no events of &ldquo;hypotension&rdquo; but occasional episodes of &ldquo;dizziness&rdquo; were observed (see section 4.8). One episode of &ldquo;syncope&rdquo; was observed in placebo and one episode on 100 mg of Vantra in phase III clinical trials. Patients with left ventricular outflow obstruction (e.g. aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be particularly sensitive to the actions of vasodilators including Vantra.</p><p><strong>Alpha-blockers</strong></p><p>Haemodynamic interactions with doxazosin and tamsulosin were studied in healthy subjects in a two-period crossover-design trial. In patients receiving stable doxazosin treatment, the placebo-subtracted mean maximum decreases in standing and supine systolic blood pressure following Vantra dosing were 2.5 mmHg and 6.0 mmHg, respectively. In total, 7/24 subjects experienced values or decreases from baseline that were of potential clinical significance following Vantra dosing (see section 4.4). In patients receiving stable tamsulosin treatment, the placebo-subtracted mean maximum decreases in standing and supine systolic blood pressure following Vantra dosing were 3.6 mmHg and 3.1 mmHg, respectively and 5/24 subjects experienced blood pressure values or decreases from baseline that were of potential clinical significance following Vantra dosing (see section 4.4). There were no reports of syncope or other severe adverse events associated with lowering of blood pressure on either cohort of subjects.</p><p><strong>Antihypertensives other than alpha-blockers</strong></p><p>A clinical study was conducted to assess the effect of Vantra on the potentiation of the blood pressure-lowering effects of selected antihypertensive medicinal products (amlodipine and enalapril). Results showed a mean maximum decrease in supine blood pressure of 2/3 mmHg compared to placebo with enalapril and 1/-1 mmHg with amlodipine when Vantra was coadministered. There was a statistically significant difference in maximum decrease from baseline in supine diastolic blood pressure with enalapril and Vantra only, which returned to baseline 4 hours after the dose of Vantra. In both cohorts, one subject experienced a decrease in blood pressure without symptoms of hypotension, which resolved within 1 hour of onset. Vantra had no effect on the pharmacokinetics of amlodipine, but amlodipine increased the maximum and total exposure of Vantra by 28% and 60%, respectively</p><p><strong>Alcohol</strong></p><p>Consumption of alcohol in combination with Vantra can increase the potential for symptomatic hypotension. In a single-dose three-way crossover design study evaluating healthy subjects, the mean maximum reduction in diastolic blood pressure was significantly greater following Vantra administered in combination with alcohol than following Vantra alone (3.2 mmHg) or alcohol alone (5.0 mmHg) (see section 4.4). Other treatments for erectile dysfunction The safety and efficacy of combinations of Vantra and other PDE5 inhibitors or other treatments for erectile dysfunction have not been studied (see section 4.4)</p><p><u><strong>Effects of other substances on Vantra</strong></u></p><p>Vantra is a substrate of and predominantly metabolised by CYP3A4. Studies have shown that medicinal products that inhibit CYP3A4 can increase Vantra exposure (see section 4.2).</p><p><strong>CYP3A4 Inhibitors</strong></p><p>Ketoconazole (400 mg daily), a selective and highly potent inhibitor of CYP3A4, increased Vantra 50 mg single-dose Cmaxand exposure (AUC) equal to 3-fold and 14-fold respectively and prolonged the half-life of Vantra to approximately 9 hours. Ritonavir (600 mg twice daily), a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9, increased Vantra 50 mg single-dose Cmax and AUC equal to approximately 2-fold and 13-fold, and prolonged the halflife of Vantra to approximately 9 hours. Other strong inhibitors of CYP3A4 (e.g. itraconazole, voriconazole, clarithromycin, nefazodone, saquinavir, nelfinavir, indinavir, atazanavir, and telithromycin) would be expected to have similar effects. Consequently, co-administration of Vantra with potent CYP3A4 inhibitors is contraindicated (see sections 4.2, 4.3 and 4.4). Erythromycin (500 mg twice daily), a moderate CYP3A4 inhibitor, increased Vantra 200 mg single-dose Cmax and AUC equal to approximately 2-fold and 3-fold, respectively, and prolonged the half-life of Vantra to approximately 8 hours. Other moderate CYP3A4 inhibitors (e.g. amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir, and verapamil) would be expected to have similar effects. Consequently, the maximum recommended dose of Vantra is 100 mg, not to exceed once every 48 hours for patients taking concomitant moderate CYP3A4 inhibitors (see section 4.2). Although specific interactions have not been studied, other CYP3A4 inhibitors, including grapefruit juice would likely increase Vantra exposure. Patients should be advised to avoid grapefruit juice within 24 hours prior to taking Vantra.</p><p><strong>CYP3A4 substrate</strong></p><p>Amlodipine (5 mg daily) increased Vantra 200 mg single-dose Cmax and AUC by approximately 28% and 60%, respectively. These exposure changes are not considered clinically significant. There was no effect of a single dose of Vantra on amlodipine plasma levels. Although specific interactions of Vantra with rivaroxaban and apixaban (both CYP3A4 substrates) have not been studied, an interaction is not expected. Cytochrome P450 Inducers The potential effect of CYP inducers, especially inducers of CYP3A4 (e.g. bosentan, carbamazepine, efavirenz, phenobarbital and rifampicin) on the pharmacokinetics and efficacy of Vantra has not been evaluated. The concomitant use of Vantra and a CYP inducer is not recommended as it may decrease the efficacy of Vantra.</p><p><u><strong>Effects of Vantra on other medicinal products</strong></u></p><p><strong>Cytochrome P450 Inhibition</strong></p><p>In in vitro studies in human liver microsomes, Vantra showed a negligible potential for drugdrug interactions with CYP1A1/2, 2A6, 2B6 and 2E1. Further, the metabolites of Vantra (M4, M16 and M27), also demonstrated a minimal inhibition of CYPs 1A1/2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4. Based on these data Vantra is not anticipated to have a significant effect on other medicinal products metabolised by these enzymes. Since the in vitro data identified potential Vantra interactions with CYPs 2C19, 2C8/9, 2D6 and 3A4, further clinical studies using omeprazole, rosiglitazone and desipramine did not reveal clinically relevant interactions with CYPs 2C19, 2C8/9 and 2D6.</p><p><strong>Cytochrome P450 Induction </strong></p><p>The potential induction of CYP1A2, CYP2B6 and CYP3A4 by Vantra evaluated in primary human hepatocytes in vitro did not reveal any potential interaction at clinically relevant concentrations. Transporters In vitro results showed for Vantra a modest potential for acting as P-gp substrate and P-gp inhibitor with digoxin as a substrate at concentrations lower than the calculated intestinal concentration. The potential of Vantra to interfere with the transport of other medicinal products mediated by P-gp is not known. Based on in vitro data, at clinically relevant concentrations Vantra could be an inhibitor of BCRP. At clinically relevant concentrations Vantra is not an inhibitor of OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3 and BSEP. The impact of Vantra on other transporters is unknown. Riociguat Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat. In clinical studies, riociguat has shown to augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including Vantra, is contraindicated (see section 4.3)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Vantra is not indicated for use in women. There are no data from the use of Vantra in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition, or postnatal development (see section 5.3).</p><p><u>Breast-feeding</u></p><p>There are no data on the use of Vantra during breast-feeding.</p><p><u>Fertility</u></p><p>There was no effect on sperm motility or morphology after single 200 mg oral doses of Vantra in healthy volunteers. Currently, no data on spermatogenesis on healthy adult males and adult males with mild ED are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vantra has minor influence on the ability to drive and use machines. As dizziness and altered vision were reported in clinical trials with Vantra, patients should be aware of how they react to Vantra before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety profile of Vantra is based on 2436 subjects exposed to Vantra during the clinical development program. The most common adverse reactions reported in clinical studies were headache, flushing, nasal and sinus congestion and back pain. Overall adverse events and adverse reactions for Vantra-treated subjects were more frequent in subjects with a Body Mass Index (BMI) &lt;25 (normal BMI subjects). In the long term clinical study, the percentage of patients who experienced adverse reactions decreased with increasing length of exposure.</p><p><u>Tabulated list of adverse reactions </u></p><p>The table below lists the adverse reactions observed in placebo-controlled clinical trials according to the MedDRA frequency convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1"><tbody><tr><td colspan="4"><p>Adverse reaction (MedDRA&nbsp;Preferred Term)&nbsp;</p></td></tr><tr><td><p>System Organ Class&nbsp;</p></td><td><p>Common&nbsp;</p></td><td><p>Uncommon&nbsp;</p></td><td><p>Rare&nbsp;</p></td></tr><tr><td><p>Infections and infestations&nbsp;</p></td><td><p> &nbsp;</p></td><td><p> &nbsp;</p></td><td><p>Influenza&nbsp;</p><p>Nasopharyngitis&nbsp;</p></td></tr><tr><td><p>Immune system disorders&nbsp;</p></td><td><p> &nbsp;</p></td><td><p> &nbsp;</p></td><td><p>Seasonal allergy&nbsp;</p></td></tr><tr><td><p>Metabolism and nutrition disorders&nbsp;</p></td><td><p> &nbsp;</p></td><td><p> &nbsp;</p></td><td><p>Gout&nbsp;</p></td></tr><tr><td><p>Psychiatric disorders&nbsp;</p></td><td><p> &nbsp;</p></td><td><p> &nbsp;</p></td><td><p>Insomnia&nbsp;</p><p>Premature ejaculation&nbsp;</p><p>Inappropriate affect&nbsp;</p></td></tr><tr><td><p>Nervous system disorders&nbsp;</p></td><td><p>Headache&nbsp;</p></td><td><p>Dizziness&nbsp;</p><p>Somnolence&nbsp;</p><p>Sinus headache&nbsp;</p></td><td><p>Psychomotor</p><p>hyperactivity&nbsp;</p></td></tr><tr><td><p>Eye disorders&nbsp;</p></td><td><p> &nbsp;</p></td><td><p>Vision blurred&nbsp;</p></td><td><p> &nbsp;</p></td></tr><tr><td><p>Cardiac disorders&nbsp;</p></td><td><p> &nbsp;</p></td><td><p>Palpitations&nbsp;</p></td><td><p>Angina pectoris&nbsp;</p><p>Tachycardia&nbsp;</p></td></tr><tr><td><p>Vascular disorders&nbsp;</p></td><td><p>Flushing&nbsp;</p></td><td><p>Hot flush&nbsp;</p></td><td><p>Hypertension&nbsp;</p></td></tr><tr><td><p>Respiratory, thoracic and&nbsp;mediastinal&nbsp;disorders&nbsp;</p></td><td><p>Nasal congestion&nbsp;</p></td><td><p>Sinus congestion&nbsp;</p><p>Dyspnoeaexertional&nbsp;</p></td><td><p>Rhinorrhoea&nbsp;</p><p>Upper respiratory tract congestion&nbsp;</p></td></tr><tr><td><p>Gastrointestinal disorders&nbsp;</p></td><td><p> &nbsp;</p></td><td><p>Dyspepsia&nbsp;</p><p>Nausea&nbsp;</p><p>Vomiting&nbsp;</p><p>Stomach discomfort&nbsp;</p></td><td><p>Dry mouth&nbsp;</p><p>Gastritis&nbsp;</p><p>Abdominal pain lower&nbsp;</p><p>Diarrhoea&nbsp;</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders&nbsp;</p></td><td><p> &nbsp;</p></td><td><p> &nbsp;</p></td><td><p>Rash&nbsp;</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders&nbsp;</p></td><td><p> &nbsp;</p></td><td><p>Back pain&nbsp;</p><p>Muscle tightness&nbsp;</p></td><td><p>Flank pain&nbsp;</p><p>Myalgia&nbsp;</p><p>Muscle spasms&nbsp;</p></td></tr><tr><td><p>Renal and urinary disorders&nbsp;</p></td><td><p> &nbsp;</p></td><td><p> &nbsp;</p></td><td><p>Pollakiuria&nbsp;</p></td></tr><tr><td><p>Reproductive system and breast disorders&nbsp;</p></td><td><p> &nbsp;</p></td><td><p> &nbsp;</p></td><td><p>Penis disorder&nbsp;</p><p>Spontaneous penile erection&nbsp;</p><p>Pruritus genital&nbsp;</p></td></tr><tr><td><p>General disorders and administration site conditions&nbsp;</p></td><td><p> &nbsp;</p></td><td><p>Fatigue&nbsp;</p></td><td><p>Asthenia&nbsp;</p><p>Chest pain&nbsp;</p><p>Influenza like illness&nbsp;</p><p>Oedema&nbsp;peripheral&nbsp;</p></td></tr><tr><td><p>Investigations&nbsp;</p></td><td><p> &nbsp;</p></td><td><p>Hepatic enzyme increased&nbsp;</p><p>Electrocardiogram abnormal&nbsp;</p><p>Heart rate increased&nbsp;</p></td><td><p>Blood pressure increased&nbsp;</p><p>Blood urine present&nbsp;</p><p>Cardiac murmur&nbsp;</p><p>Prostate specific antigen increased&nbsp;</p><p>Weight increased&nbsp;</p><p>Blood bilirubin increased&nbsp;</p><p>Blood creatinine increased&nbsp;</p><p>Body temperature increased&nbsp;</p></td></tr></tbody></table><p><u>Description of selected adverse reactions observed with other PDE5 inhibitors</u></p><p>Non-arteritic anterior ischaemic optic neuropathy (NAION) and sudden loss of hearing have been reported in a small number of postmarketing and clinical trial cases with other PDE5 inhibitors. No cases were reported during clinical trials of Vantra (see section 4.4). Priapism has been reported in a small number of post-marketing and clinical trial cases with other PDE5 inhibitors. No cases were reported during clinical trials of Vantra. Haematuria, haematospermia and penile haemorrhage has been reported in a small number of post-marketing and clinical trial cases with other PDE5 inhibitors. Hypotension has been reported post marketing with other PDE5 inhibitors, and dizziness, a symptom commonly caused by lowered blood pressure, has been reported in clinical trials with Vantra (see section 4.5).</p><p><u>Reporting of suspected adverse reactions</u></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>To report any side effect(s):</p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><br />Single dose of up to 800 mg of Vantra have been given to healthy subjects and multiple daily doses up to 300 mg have been given to patients. Adverse reactions were similar to those seen at lower doses but incidence rates and severities were increased.</p><p>In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as Vantra is highly bound to plasma proteins and it is not eliminated in the urine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in erectile dysfunction. ATC code: G04BE10.</p><p><u>Mechanism of action</u></p><p>Vantra is a highly selective and potent, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5. When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by Vantra produces increased levels of cGMP in the corpus cavernosum of the penis. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. Vantra has no effect in the absence of sexual stimulation.</p><p><u>Pharmacodynamic effects</u></p><p>Studies in vitro have shown that Vantra is highly selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (&gt; 100-fold for PDE6; &gt; 1,000-fold for PDE4, PDE8 and PDE10; &gt; 5,000-fold for PDE2 and PDE7; &gt; 10,000-fold for PDE1, PDE3, PDE9, and PDE11). Vantra is &gt; 100-fold more potent for PDE5 than PDE6, which is found in the retina and is responsible for phototransduction. The approximately 20,000-fold selectivity for PDE5 versus PDE3, and enzyme found in heart and blood vessels, is important because PDE3 is involved in control of cardiac contractility. In a penile plethysmography (RigiScan) study, Vantra 200 mg produced erections considered sufficient for penetration (60% rigidity by RigiScan) in some men as early as 20 minutes after dosing and overall response of these subjects to Vantra was statistically significant, compared to placebo, in the 20-40 minute time interval</p><p><u>Clinical efficacy and safety</u></p><p>In clinical trials, Vantra was assessed for its effect on the ability of men with erectile dysfunction (ED) to achieve and maintain an erection sufficient for satisfactory sexual activity. Vantra was evaluated in 4 randomized, double-blind, placebo-controlled, parallel group trials of up to 3 months in duration in the general population with ED, in patients with Type 1 or Type 2 diabetes and ED, and in patients with ED following bilateral nerve-sparing radical prostatectomy. The fourth study investigated the onset of action of Vantra at two doses (100 and 200 mg) in terms of per-subject proportion of sexual attempts resulting in satisfactory completion of sexual intercourse. A total of 1774 patients received Vantra, which was taken as needed at doses of 50 mg (one study), 100 mg and 200 mg (four studies), respectively. Patients were instructed to take 1 dose of study medication approximately 30 minutes prior to initiation of sexual activity. In the fourth study patients were encouraged to attempt sexual intercourse approximately 15 minutes post-dosing, to assess the onset of the erectogenic effect of Vantra, taken on an as needed basis, at 100 and 200 mg dose.&nbsp;In addition, a subset of patients was enrolled into an open-label extension trial with 493 patients receiving Vantra for at least 6 months and 153 patients for at least 12 months. Patients were initially assigned to Vantra 100 mg and at any point during the trial, they could request to have their dose of Vantra increased to 200 mg or decreased to 50 mg based on their individual response to treatment. In all trials, statistically significant improvement in all primary efficacy measures were observed for all three doses of Vantra compared to placebo. These differences were maintained with long term treatment (as per studies in the general ED population, in diabetics with ED and in men with ED following bilateral nerve-sparing radical prostatectomy and in the open-label extension trial). In the general population with ED, the mean percentage of attempts resulting in successful intercourse was approximately 47%, 58%, and 59% for the 50 mg, 100 mg, and 200 mg Vantra groups, respectively, as compared with approximately 28% for placebo. In men with either Type 1 or Type 2 diabetes mellitus, the mean percentage of attempts resulting in successful intercourse was approximately 34% and 40% for the 100 mg and 200 mg Vantra groups, respectively, compared to approximately 21% for the placebo group. In men with ED following bilateral nerve-sparing radical prostatectomy, the mean percentage of attempts resulting in successful intercourse was approximately 23% and 26% for the 100 mg and 200 mg Vantra groups, respectively, compared to approximately 9% for placebo. In the Time to onset study, Vantra demonstrated statistically significant improvement in the primary efficacy variable (average per subject proportion of successful responses by time after dose administration, to the Sexual Encounter Profile 3 - SEP3) as compared with placebo, resulting in successful intercourse in 24.71% of the attempts for the 100 mg dose and 28.18% for the 200 mg dose at approximately 15 minutes after dosing compared to 13.78% for placebo. Across all of the pivotal trials of Vantra, the percentage of successful intercourse attempts was significantly higher for all doses of Vantra compared to placebo for attempts at all post-dosing time intervals examined</p><p><u>Pediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Vantra in all subsets of the paediatric population in erectile dysfunction (see section 4.2 for information on paediatric use)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vantra is rapidly absorbed after oral administration, with a median Tmax of 30 to 45 minutes. Its pharmacokinetics are dose-proportional over the recommended dose range. It is eliminated predominantly by hepatic metabolism (mainly CYP3A4). The concomitant use of potent CYP3A4 inhibitors (e.g. ketoconazole and ritonavir) is associated with increased plasma exposure of Vantra (see section 4.5). Vantra has a terminal half-life of approximately 6-17 hours.</p><p><u>Absorption </u></p><p>Vantra is rapidly absorbed. Maximum observed plasma concentrations are reached within 0.5 to 0.75 hours of oral dosing in the fasted state. When Vantra is taken with a high fat meal, the rate of absorption is reduced with a mean delay in Tmaxof 1.25 hours and a mean reduction in&nbsp;Cmax of 39% (200 mg). There was no effect on the extent of exposure (AUC). The small changes in VantraCmax are considered to be of minimal clinical significance.</p><p><u>Distribution</u></p><p>Vantra is approximately 99% bound to plasma proteins. Protein binding is independent of total active substance concentrations, age, renal and hepatic function. Vantra was not found to accumulate in plasma when dosed 200 mg twice daily over 7 days. Based upon measurements of Vantra in semen of healthy volunteers 45-90 minutes after dosing, less than 0.0002% of the administered dose may appear in the semen of patients.</p><p><u>Biotransformation</u></p><p>Vantra is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes. The plasma concentrations of the major circulating metabolites, M4 and M16, are approximately 23% and 29% that of the parent compound, respectively. The M4 metabolite shows a phosphodiesterase selectivity profile similar to that of Vantra and an in vitro inhibitory potency for PDE5 18% of that of Vantra. Therefore, M4 accounts for approximately 4% of total pharmacologic activity. The M16 metabolite was inactive against PDE5.</p><p><u>Elimination </u></p><p>Vantra is extensively metabolised in humans. After oral administration, Vantra is excreted as metabolites predominantly in the faeces (approximately 63% of administered oral dose) and to a lesser extent in the urine (approximately 21% of the administered oral dose).</p><p><u>Other special populations</u></p><p>Older men Older patients (65 years or over) had comparable exposure to that seen in younger patients (18- 45 years). However, data on subjects older than 70 years are limited. Renal impairment In subjects with mild (creatinine clearance &ge; 50 - &lt; 80 mL/min) and moderate (creatinine clearance &ge; 30 - &lt; 50 mL/min) renal impairment, the pharmacokinetics of a single 200 mg dose of Vantra were not altered. There are no data available for subjects with severe renal insufficiency or end-stage renal disease on haemodialysis. Hepatic impairment Subjects with mild hepatic impairment (Child-Pugh A) had comparable exposure to subjects with normal hepatic function when a single dose of 200 mg Vantra was administered. The exposure 4 hours post-dose was lower in subjects with moderate hepatic impairment (Child-Pugh B) compared to subject with normal hepatic function after 200 mg of Vantra. The maximum concentration and exposure was similar to that observed after subjects with normal hepatic function received an efficacious Vantra 100 mg dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction.</p><p>In a rat fertility and early embryonic development trial, a decrease in fertility and sperm motility, altered estrous cycles, and an increased percentage of abnormal sperm occurred at 1000 mg/kg/day, a dose which also caused parental toxicity in the treated males and females. No effects on fertility or sperm parameters were noted at doses up to 300 mg/kg/day (in male rats 9 times human exposure based on unbound AUC at a dose of 200 mg). There were no treatment-related testicular findings in mice or rats treated with doses up to 600 or 1000 mg/kg/day for 2 years, and no testicular findings in dogs treated with Vantra for 9 months at exposures 110 times human exposure at the Maximum Recommended Human Dose (MRHD). In pregnant rats, no evidence of teratogenicity, embryotoxicity, or fetotoxicity was observed at doses up to 300 mg/kg/day (approximately 15 times the MRHD on a mg/m2 basis in a 60 kg subject). At a maternally toxic dose of 1000 mg/kg/day (approximately 49 times the MRHD on a mg/m2 basis), decreased fetal body weight occurred with no signs of teratogenicity. In pregnant rabbits, no teratogenicity, embryotoxicity or fetotoxicity was observed at doses up to 240 mg/kg/day (approximately 23 times the MRHD on a mg/m2 basis. In the rabbit study, maternal toxicity was observed at 240 mg/kg/day. In a rat pre- and post-natal development study, pups exhibited persistent decreases in body weight at 300 mg/kg/day and higher (approximately 15 times the MRHD on a mg/m2 basis) and delayed sexual development at 600 mg/kg/day (approximately 29 times the MRHD on a mg/m2 basis).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The other ingredients are Mannitol B.P, Fumaric Acid NF, Klucel EXF Pharm (Hydroxypropyl Cellulose ), Iron Oxide Yellow, Hydroxypropyl Methylcellulose Low-S., Calcium Carbonate Precipitated, and Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24Months/2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear PVC/PE/PVDC 250/25/120 95mm Each pack of Vantra 50 mg tablets contains 4, 12, and 30 tablets. Each pack of Vantra 100 mg tablets contains 4, and 12 tablets. Each pack of Vantra 200 mg tablets contains 4, and 12 tablets. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
Al-Qassim pharmaceutical plant
Saudi Pharmaceutical Industries & Medical Appliance Corporation
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>